FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2495201059> ?p ?o ?g. }

• W2495201059 endingPage "1276" @default.
• W2495201059 startingPage "1267" @default.
• W2495201059 abstract "Objective: Osteogenesis imperfecta (OI) is characterized by low bone mass and recurrent fractures. Adults with OI are often treated with oral or intravenous bisphosphonates (BPs). We investigated the clinical phenotypes of adult OI patients and prospectively compared the efficacy of oral alendronate (ALN) with intravenous zoledronic acid (ZOL) in OI patients. Methods: This 24-month, observational, randomized clinical study included 60 adult patients with OI. We compared the differences in bone mineral density (BMD) and bone turnover biomarkers between OI adults and healthy subjects. Thereafter, OI patients were randomized at a 2:1 ratio to receive either weekly oral ALN 70 mg or once-yearly infusion of ZOL 5 mg. The efficacy outcomes were changes in BMD, bone turnover biomarkers, and fracture incidence. Results: Adult OI patients had significantly lower BMD and significantly higher cross-linked C-telopeptide of type I collagen (β-CTX) levels than age-/sex-/BMI-matched healthy subjects. A total of 52 patients completed the 24-month clinical study. BMD at lumbar spine, femoral neck, and total hip were equivalently elevated in the ALN (10.5, 13.2, and 14.7%, respectively) and ZOL (11.3, 13.7, and 11.7%, respectively; all P>.05) groups. Serum alkaline phosphatase decreased by 30.3% in the ALN group and 37.3% in the ZOL group (P =.12), and β-CTX decreased by 58.0% in the ALN group and 63.6% in the ZOL group (P =.48). Compared to the prior fracture rates, clinical fracture incidences were decreased in the ALN and ZOL groups (both P<.05). Conclusion: Adults with OI present significantly lower bone mass and higher bone resorption biomarkers than healthy populations. Oral ALN and intravenous ZOL are equally effective at increasing BMD and inhibiting bone turnover in adults with OI. The treatment may reduce fractures in this study, but further efforts are still needed to demonstrate the anti-fracture efficacy of BPs. Abbreviations: 25OHD = 25-hydroxyvitamin D ALN = alendronate ALP = alkaline phosphatase BMD = bone mineral density BMI = body mass index BP = bisphosphonate β-CTX = cross-linked C-telopeptide of type I collagen FN = femoral neck LS = lumbar spine OI = osteogenesis imperfecta RCT = randomized controlled trial TH = total hip ZOL = zoledronic acid" @default.
• W2495201059 created "2016-08-23" @default.
• W2495201059 creator A5007477169 @default.
• W2495201059 creator A5008659449 @default.
• W2495201059 creator A5009884211 @default.
• W2495201059 creator A5011545641 @default.
• W2495201059 creator A5015025675 @default.
• W2495201059 creator A5031831121 @default.
• W2495201059 creator A5034938461 @default.
• W2495201059 creator A5065503728 @default.
• W2495201059 creator A5065763596 @default.
• W2495201059 creator A5067701828 @default.
• W2495201059 creator A5083691374 @default.
• W2495201059 date "2016-11-01" @default.
• W2495201059 modified "2023-09-25" @default.
• W2495201059 title "The Clinical Characteristics and Efficacy of Bisphosphonates in Audlt Patients with Osteogenesis Impergecta" @default.
• W2495201059 cites W1490842926 @default.
• W2495201059 cites W1508998309 @default.
• W2495201059 cites W1592271535 @default.
• W2495201059 cites W1774930055 @default.
• W2495201059 cites W1967802680 @default.
• W2495201059 cites W1972974851 @default.
• W2495201059 cites W1980139196 @default.
• W2495201059 cites W1997837627 @default.
• W2495201059 cites W1998076734 @default.
• W2495201059 cites W2004928635 @default.
• W2495201059 cites W2011610305 @default.
• W2495201059 cites W2034422185 @default.
• W2495201059 cites W2034553603 @default.
• W2495201059 cites W2037631967 @default.
• W2495201059 cites W2039449445 @default.
• W2495201059 cites W2044078197 @default.
• W2495201059 cites W2046486252 @default.
• W2495201059 cites W2046815985 @default.
• W2495201059 cites W2056536222 @default.
• W2495201059 cites W2066047732 @default.
• W2495201059 cites W2080886083 @default.
• W2495201059 cites W2099431176 @default.
• W2495201059 cites W2103591738 @default.
• W2495201059 cites W2106586395 @default.
• W2495201059 cites W2124027205 @default.
• W2495201059 cites W2124925461 @default.
• W2495201059 cites W2134304734 @default.
• W2495201059 cites W2143127449 @default.
• W2495201059 cites W2153852234 @default.
• W2495201059 cites W2168059778 @default.
• W2495201059 cites W2212926481 @default.
• W2495201059 cites W2330433191 @default.
• W2495201059 cites W2387510378 @default.
• W2495201059 cites W2616532386 @default.
• W2495201059 cites W4211060251 @default.
• W2495201059 cites W617235124 @default.
• W2495201059 doi "https://doi.org/10.4158/ep151184.or" @default.
• W2495201059 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27482615" @default.
• W2495201059 hasPublicationYear "2016" @default.
• W2495201059 type Work @default.
• W2495201059 sameAs 2495201059 @default.
• W2495201059 citedByCount "7" @default.
• W2495201059 countsByYear W24952010592019 @default.
• W2495201059 countsByYear W24952010592020 @default.
• W2495201059 countsByYear W24952010592021 @default.
• W2495201059 countsByYear W24952010592022 @default.
• W2495201059 countsByYear W24952010592023 @default.
• W2495201059 crossrefType "journal-article" @default.
• W2495201059 hasAuthorship W2495201059A5007477169 @default.
• W2495201059 hasAuthorship W2495201059A5008659449 @default.
• W2495201059 hasAuthorship W2495201059A5009884211 @default.
• W2495201059 hasAuthorship W2495201059A5011545641 @default.
• W2495201059 hasAuthorship W2495201059A5015025675 @default.
• W2495201059 hasAuthorship W2495201059A5031831121 @default.
• W2495201059 hasAuthorship W2495201059A5034938461 @default.
• W2495201059 hasAuthorship W2495201059A5065503728 @default.
• W2495201059 hasAuthorship W2495201059A5065763596 @default.
• W2495201059 hasAuthorship W2495201059A5067701828 @default.
• W2495201059 hasAuthorship W2495201059A5083691374 @default.
• W2495201059 hasConcept C120665830 @default.
• W2495201059 hasConcept C121332964 @default.
• W2495201059 hasConcept C125870589 @default.
• W2495201059 hasConcept C126322002 @default.
• W2495201059 hasConcept C126894567 @default.
• W2495201059 hasConcept C131075544 @default.
• W2495201059 hasConcept C142724271 @default.
• W2495201059 hasConcept C160160445 @default.
• W2495201059 hasConcept C170033053 @default.
• W2495201059 hasConcept C181199279 @default.
• W2495201059 hasConcept C185592680 @default.
• W2495201059 hasConcept C2775854910 @default.
• W2495201059 hasConcept C2776326535 @default.
• W2495201059 hasConcept C2776541429 @default.
• W2495201059 hasConcept C2776886416 @default.
• W2495201059 hasConcept C2777251235 @default.
• W2495201059 hasConcept C2777668750 @default.
• W2495201059 hasConcept C2779329777 @default.
• W2495201059 hasConcept C55493867 @default.
• W2495201059 hasConcept C61511704 @default.
• W2495201059 hasConcept C71924100 @default.
• W2495201059 hasConcept C90924648 @default.
• W2495201059 hasConceptScore W2495201059C120665830 @default.

• next